Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B
Status: Not yet recruiting
Phase of Trial: Phase III/IV
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Trenonacog alfa (Primary)
- Indications Haemophilia B
- Focus Registrational; Therapeutic Use
- Sponsors Aptevo Therapeutics
- 07 Nov 2019 According to an Aptevo Therapeutics media release, company has Commenced enrolling clinical sites in preparation to begin dosing in this study.
- 01 Nov 2019 Planned initiation date changed from 15 Aug 2019 to 15 Nov 2019.
- 18 Mar 2019 According to an Aptevo Therapeutics media release, the company expects to commence patient dosing in Q3 2019.